PM-TW-FFV-PPTX-240123 Date of preparation: 2024.11 Trademarks are owned by or licensed to the GSKgroup of companies Relvar Ellipta was developed in collaboration with INNOVIVA 不良事件通報程序: (02)23126836/oax40892@gsk.com 葛蘭素史克藥廠地址: 100台北市忠孝西路一段66號23樓 Intended for Taiwan Healthcare Professionals only

## Asthma and Severe Asthma Remission: What is it and can all patients achieve it?

## 莊立邦 Li-Pang Chuang MD; PhD



Director, Department of Pulmonary Infection and Immunology, Chang Gung Memorial Hospital, Linkou Associate Professor, School of Medicine, Chang Gung University, Taoyuan



20241117

## **Take Home Messages**

- 1. Lung function and patient symptoms are key factors in determining whether clinical remission can be achieved. It's important to closely monitor the patient.
- 2. If the patient's lung function and symptoms remain unstable, it may be advisable to consider stepping up to Trelegy 200, from the perspective of achieving clinical remission.
- 3. Biologics with anti-IL5 for SEA can achieved clinical remission in one-third patients for at least 2 years.
- 4. Early escalation to triple therapy or biologics will also have a higher likelihood of achieving clinical remission in the future.